Ian Adamson Joins Maxwellia as Strategic Advisor
Appointment underlines company’s commitment to put the ‘P’ back into pharmacy and drive UK shift to self-care
Alderley Park UK - May 2022 - Maxwellia’s pioneering vision, exponential growth, and media grabbing headlines over the past two years has attracted industry expert Ian Adamson who joins the company as strategic advisor. Ian’s role will be to work with Maxwellia to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist.
Ian brings over 30 years’ international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl.
Ian’s appointment follows the landmark reclassification of the progestogen only pill by the MHRA*, a change spearheaded by Maxwellia, and the company’s subsequent launch of its first product Lovima® in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia’s new pharmacy brand, Aquiette® 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone. (N.B. this form of treatment for symptoms of overactive bladder is currently only available as a prescription only medicine and therefore, Aquiette® is not yet approved for sale in pharmacy).
Commenting on his new role Ian said, “Passion, experience and vision are three words which describe the Maxwellia team and a key reason for me wanting to work with such an exceptionally talented group of people. I am delighted to be involved in the next stage of Maxwellia’s development both domestically and internationally. The company has an impressive pipeline of switch medicines which will help people manage their health without the need for a GP appointment and prescription, helping reduce the load on an over-stretched NHS”.
Maxwellia founder and CEO, Anna Maxwell says: “Ian’s understanding of the consumer healthcare landscape and experience with leading global pharmacy brands will be invaluable as we continue apace with our vision of empowering and enabling greater self-care and firmly position the pharmacist at the heart of the nation’s public health.”
For more information visit www.maxwellia.com.
